Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
#1026
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Aim(s): To assess the systemic treatment of Ki-67 5-10% metastatic GEP-NET.
Materials and methods: Two-hundred and seventeen pts with metastatic GEPNET were attended in a Spanish Medical Oncology Department from 2005-2012. Twenty of these 217 (9%) which had Ki-67 5-10% GEPNET were analysed.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Jiménez-Fonseca P, Carmona A, Faez L, Solis P, Rodriguez D,
Keywords: Ki-67, pancreatic neuroendocrine tumor, systemic therapy,
To read the full abstract, please log into your ENETS Member account.